Tetiana A. Serheieva

Tetiana A. Serheieva

Auto-generated profile, based on publicly available information

Tetiana A. Serheieva

ДУ «Інститут епідеміології та інфекційних хвороб ім. Л. В. Громашевського НАМН України

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2026 in One Health Journal
Verified
Journal Article
Open access
PDF file
VZV. I. Zadorozhna
V. I. Zadorozhna
NVN. P. Vynnyk
N. P. Vynnyk
TST. A. Sergeeva
T. A. Sergeeva
Anton GerilovychAnton Gerilovych
Anton Gerilovych
Pneumococcal infection is caused by more than 100 serotypes of S. pneumoniae (Spn), as well as non-encapsulated pneumococci. The greatest danger is posed by invasive pneumococcal infections (IPI), when the pathogen is found in locations that should be sterile. IPI most often includes meningitis and septic conditions. Spn caused between 929,000 and 1.4 million deaths worldwide only in 2019. The widespread use of pneumococcal conjugate vaccines (PCVs) for children in vaccination programs has significantly influenced the epidemiological process of this infection, gradually leading to a decrease in the effectiveness of PCVs and accompanied by an increase in the number of Spn serotypes in PCVs due to previously non-vaccinal serotypes (NVST), which became invasive and relevant in the process of expanding the scope of vaccination. The aim of the study was to analyze changes in the invasiveness of Spn from different serotypes against the background of vaccination, the evolution of PCVs, and the prospects for vaccine control of pneumococcal infection. The paper provides an analysis of literature data on the high efficacy of PCVs against IPI caused by vaccine serotypes (VST) Spn, the gradual serotype change of invasive Spn and their acquisition of epidemic relevance, multidrug resistance; risks associated with nonencapsulated Spn; dynamics of increasing valency of PCV serotypes (from PCV7 to PCV21, development of PCV24, PCV25, and PCV31) and their further impact on the epidemic process in different countries and regions of the world. The impact of vaccination on the composition of the upper respiratory tract microbiome was discussed, as well as differences in IPI levels in different territories and their causes. It was demonstrated that vaccination against pneumococcal infection does not provide a warranty of protection even against fatal cases due to the acquisition of highly invasive properties by NVST. The use of PCVs does not adequately affect the intensity of circulation of some VSTs (types 3 and 19A). The dynamics of IPI levels (2010–2022) and changes in the dominant Spn serotypes were analyzed using the example of EU/EEA countries. In 17 (63%) of 27 countries, there was a tendency for IPI to increase against the backdrop of long-term vaccination; in 3 (11%), there was a stable trend; in 7 (26%), there was a decline in morbidity. However, even with a downward trend, the IPI levels in some countries exceeded those in some countries where an upward trend was observed. The total IPI cases for these countries did not actually decrease and ranged from 5.7 to 6.4 per 100,000 population, with a moderate upward trend. The results of our analysis show that the widespread use of PCVs, even with an increase in their valence, will require constant replacement of current serotypes, without actually significantly affecting IPI levels. This does not allow us to talk about vaccine control of IPI either now or in the future. We see the only optimal solution for curbing the accelerated artificial evolution of Spn, stabilizing the epidemic process, and optimizing the use of PCVs as directing the vaccination strategy toward medical and epidemic risk groups.

13 May 2024 in Інфекційні хвороби
Verified
Journal Article
Open access
PDF file
ТСТ. А. Сергеєва
Т. А. Сергеєва
ВЗВ. І. Задорожна
В. І. Задорожна
НБН. С. Бугаєнко
Н. С. Бугаєнко
SUMMARY. Hepatitis B remains a serious global medico-social problem. The COVID-19 pandemic has interrupted positive developments in the implementation of the WHO Global Strategy to combat viral hepatitis due to delays in screening, diagnosis, initiation of patient treatment, etc. In Ukraine, the crisis of COVID-19 was exacerbated by the crisis of martial law. In 2020–2021, the number of registered hepatitis B cases in Ukraine decreased significantly compared to 2015–2019, more pronounced for chronic hepatitis B. Starting from 2022, despite the war and incomplete reporting, the incidence began to rise moderately, and in 2023 for chronic infection approached the «pre-COVID» level. In 2022–2023, an increase in the incidence of acute hepatitis B was observed among children under 1 year, 1–4, and 5–9 years, that is, those who should be protected by vaccination. The coverage level of vaccination against hepatitis B in Ukraine is unsatisfactory – during 2015–2023, it was 25.4–79.8 %, which is significantly lower than the WHO recommendation, and coverage rates differ significantly by region of Ukraine (58.0–98.9 % in 2023). On average, out of 6 people with HBsAg detected during diagnostic examination, only 1 made it to official registration and, probably, to medical observation. Growth in the dynamics of 2020–2022 in the frequency of detection of the hepatitis B virus (HBV) marker, namely HBsAg, among children born to HBsAg-carrier mothers, children of the 1st year of life – recipients of blood and its components, patients with venereal diseases, patients of drug dispensaries, those who are in hospital treatment for a long time, children of orphanages and special boarding schools should be considered from the standpoint of the risks of implementing natural and artificial ways of HBV transmission. The epidemic situation of hepatitis B, which is classified as an infection relevant during the war, in Ukraine remains tense, quantitatively underestimated, with a tendency to worsen. Гепатит В залишається серйозною глобальною медико-соціальною проблемою. Пандемія COVID-19 перервала позитивні зрушення у виконанні Глобальної стратегії ВООЗ щодо боротьби з вірусними гепатитами через затримки скринінгу, діагностики, початку лікування пацієнтів тощо. В Україні криза COVID-19 посилилася кризою воєнного стану. У 2020–2021 рр. в Україні кількість зареєстрованих випадків гепатиту В суттєво зменшилася порівняно з 2015–2019 рр., значніше для хронічного гепатиту В. Починаючи з 2022 р., попри війну та неповну звітність, захворюваність почала помірно зростати, а в 2023 р. для хронічної інфекції наблизилась до «доковідного» рівня. У 2022–2023 рр. підйом захворюваності на гострий гепатит В спостерігався серед дітей до 1 року, 1–4 та 5–9 років, тобто тих, які повинні бути захищені вакцинацією. Рівень охоплення вакцинацією проти гепатиту В в Україні є незадовільним – протягом 2015–2023 рр. він дорівнював 25,4–79,8 %, що значно нижче рекомендованого ВООЗ, і показники охоплення суттєво відрізняються за регіонами України (58,0–98,9 % у 2023 р.). У середньому з 6 осіб із виявленим HBsAg при діагностичному обстеженні лише 1 потрапляла до офіційної реєстрації та, ймовірно, – до медичного спостереження. Зростання в динаміці 2020–2022 р. частоти виявлення маркера вірусу гепатиту В (HBV), а саме HBsAg, серед дітей, народжених від матерів-носіїв HBsAg, дітей 1-го року життя – реципієнтів крові та її компонентів, хворих на венеричні хвороби, пацієнтів наркодиспансерів, тих, які довго перебувають на стаціонарному лікуванні, дітей дитячих будинків та спецінтернатів слід розглядати з позиції ризиків реалізації природних і штучних шляхів передачі HBV. Епідемічна ситуація з гепатиту В, який відносять до інфекцій, актуальних під час війни, в Україні залишається напруженою, кількісно недооціненою, з тенденцією до погіршення.

28 March 2024 in Modern pediatrics. Ukraine
Verified
Journal Article
Open access
PDF file
VZV.I. Zadorozhna
V.I. Zadorozhna
NVN.P. Vynnyk
N.P. Vynnyk
TST.A. Serheieva
T.A. Serheieva
IMI.L. Marichev
I.L. Marichev
SBS.I. Brighata
S.I. Brighata
IDI.V. Demchishina
I.V. Demchishina
Since 2001, due to the effectiveness of vaccines, the Measles Elimination Initiative was introduced. However, there are periodic increases in its incidence. In terms of intensity, the measles epidemic process in Ukraine in 2017-2019 can be considered as an epidemic. In 2022, 205,153 cases of measles were reported worldwide (67% more than in 2021). In 2023, this indicator in the European Region of the World Health Organization increased 30 times compared to 2022. Thus, measles remains a pressing problem. Aim - to analyze the incidence of measles, particularly among vaccinated individuals, the state of specific population immunity, as well as to assess of the current epidemic situation. Materials and methods. An analysis was carried out: the incidence of measles in Ukraine (2017-11/30/2023), its level among vaccinated people (2017-2022), the rates of vaccination against measles, mumps and rubella (MMR) (2016-2023), the state of specific population immunity of the population (2019-2022). Descriptive-evaluative and analytical approaches of the epidemiological method, as well as methods of mathematical statistics were used. Results and conclusions. The previous rise in the incidence of measles in Ukraine (2017-2019) and the beginning of the current one (2023) occurred against the background of unsatisfactory coverage of the first and second doses of the MMR vaccinations (2016 - 45.5% and 30.2%; 2022 - 74.1% and 69.1%, respectively). The population of all age groups is involved in the intensification of the measles epidemic process (with the exception of patients who were ill in the pre-vaccination period). The high effectiveness of MMR-1 for children aged 1 to 4 years has been shown, with its decrease with increasing age and gaps in the coverage of MMR-2 for children aged 6 years. Unvaccinated adults remain at risk. In 2019-2021, the proportion of individuals with a protective level of specific antibodies was 89-91%, and by age groups - 83-91%. A significant decrease of this indicator was observed in 2022 compared to 2021 in all age groups, with the exception of children aged 1-4 years. Ensuring proper vaccine prevention in Ukraine is one of the primary tasks for reducing the cyclical outbreaks of measles and achieving its elimination. No conflict of interests was declared by the authors. Із 2001 р. завдяки ефективності вакцин було запроваджено Ініціативу елімінації кору. Однак періодично простежуються підйоми його рівня захворюваності. Епідемічний процес кору в Україні за інтенсивністю протягом 2017-2019 рр. можна розцінювати як епідемію. У 2022 р. у світі було зареєстровано 205 153 випадків кору (на 67% більше ніж у 2021 р.). У 2023 р. цей показник в Європейському регіоні Всесвітньої організації охорони здоров’я зріс у 30 разів порівняно з 2022 р. Таким чином, кір є і досі актуальною проблемою. Мета - проаналізувати захворюваність на кір (зокрема, серед вакцинованих осіб) та стан специфічного популяційного імунітету, а також надати оцінку теперішній епідемічній ситуації. Матеріали та методи. Проведено аналіз: захворюваності на кір в Україні (2017-30.11.2023 р.) та його рівня серед вакцинованих (2017-2022 рр.); показників охоплення щепленнями вакциною проти кору, епідемічного паротиту та краснухи (КПК) (2016-2023 рр.); стану специфічного популяційного імунітету населення (2019-2022 рр.). Використано описово-оціночні і аналітичні підходи епідеміологічного методу, а також методи математичної статистики. Результати та висновки. Попередній епідемічний підйом захворюваності на кір в Україні (2017-2019 рр.) і початок поточного (2023 р.) відбувалися на тлі незадовільного стану охоплення першим і другим щепленнями КПК (2016 р. - 45,5% та 30,2%; 2022 р. - 74,1% та 69,1% відповідно). В інтенсифікації епідемічного процесу кору задіяно населення всіх вікових груп (за винятком пацієнтів, що перехворіли в довакцинальний період). Показано високу ефективність КПК-1 для дітей віком від 1 до 4 років із її зниженням зі збільшенням віку та прогалини щодо охоплення КПК-2 дітей у віці 6 років. Невакциновані дорослі належать до групи ризику. У 2019-2021 рр. частка осіб із захисним рівнем специфічних антитіл становила 89-91%, а за віковими групами - 83-91%. Порівняно з 2021 р. у 2022 р. простежувалося достовірне зниження цього показника в усіх вікових групах, за винятком дітей 1-4 років. Забезпечення належної вакцинопрофілактики в Україні є одним із першочергових...

28 April 2025 in Modern pediatrics. Ukraine
Verified
Journal Article
Open access
PDF file
VZV.I. Zadorozhna
V.I. Zadorozhna
NVN.P. Vynnyk
N.P. Vynnyk
TST.A. Serheieva
T.A. Serheieva
APA.P. Podavalenko
A.P. Podavalenko
In 1998, the World Health Assembly set a goal to reduce the incidence of pertussis to 1 case per 100,000 population. This target has not been achieved, and after the COVID-19 pandemic, the epidemic situation with pertussis has become more complicated for Ukraine and many countries. The aim is to determine the epidemiological features of pertussis in Ukraine, taking into account the impact of the COVID-19 pandemic and martial law. Materials and methods. The incidence of pertussis in Ukraine, its structure by age and territory, and vaccination coverage data were analyzed. A complex of epidemiological methods combined with mathematical statistics was applied. Results and conclusions. After a sharp decrease in the incidence of pertussis in Ukraine against the backdrop of the COVID-19 pandemic in 2021-2022, it increased sharply in 2023-2024, which was complicated by martial law. A similar trend was observed in many other countries. The highest incidence rates were observed among children of the first year of life (362.15 per 100 thousand) and aged 1-4 years (114.13). This requires the introduction of revaccination against pertussis in children aged 6 years. During the epidemic upsurge in 2023-2024 the largest proportion of cases occurred in the western regions of Ukraine (73.8% and 53.4%, respectively), which were most involved in wartime migration processes and where vaccination coverage levels were low in previous years. The problem of pertussis losing the character of a vaccine-controlled infection requires further study, in particular, taking into account changes in the biological properties of Bordetella pertussis against the background of long-term vaccine prophylaxis.

6 September 2025 in CHILD`S HEALTH
Verified
Journal Article
Open access
VZV.I. Zadorozhna
V.I. Zadorozhna
NVN.P. Vynnyk
N.P. Vynnyk
TST.A. Serheieva
T.A. Serheieva
APA.P. Podavalenko
A.P. Podavalenko
Background. Whole-cell and acellular pertussis vaccines are used for the prevention of the disease. Following the COVID-19 pandemic, an increase in pertussis incidence has been observed in several countries, indicating a decline in vaccine-controlled disease management. The purpose was to assess global and regional trends in the pertussis epidemic process and analyze the causes of increasing incidence, particularly among vaccinated individuals. Materials and methods. A systematic review of publications and reports was conducted using databases (PubMed, Scopus, Web of Science, Google Scholar) and sources from the WHO, CDC, and ECDC. The analysis covered incidence trends, vaccine effectiveness, the rise in cases among vaccinated individuals, regional epidemiological patterns, and progress in the development of new vaccines. For Ukraine, incidence rates during the first 6 months of 2024 and 2025 were compared. Results. The highest increase in incidence was recorded in the WHO European Region (53.6 % of global cases). In Ukraine, following an outbreak in 2024 (7,545 cases; 18.4 per 100,000 population), 842 cases were reported in the first half of 2025 that is 5.8 times fewer, suggesting a return to the cyclical nature of the infection. Official incidence rates in Ukraine are underestimated due to calculations based on the pre-war population size, which is particularly relevant under wartime conditions. Underdiagnosis is confirmed by serological studies among healthy individuals and patients with prolonged cough. Asymptomatic persistence of Bordetella pertussis and underdiagnosis of manifest forms pose significant risks for infants who have not yet been immunized. A high proportion of cases among vaccinated individuals, the emergence of antibiotic-resistant strains, and the waning of post-vaccination immunity underscore the urgent need for more effective vaccines aligned with the antigenic characteristics of circulating strains. Conclusions. A decline in vaccine-controlled management and changes in the epidemiological features of pertussis have been observed, particularly following the ­COVID-19 pandemic. In Ukraine, after a peak in 2024, incidence has decreased in 2025, indicating the cyclical nature of the infection. Underdiagnosis and statistical distortions remain pressing issues. Vaccination strategies differ across countries, and efforts to develop new vaccines considering pathogen evolution are ongoing.

10 August 2026 in Mikrobiolohichnyi Zhurnal
Verified
Journal Article
Open access
PDF file
VZV.I. Zadorozhna
V.I. Zadorozhna
NVN.P. Vynnyk
N.P. Vynnyk
TST.A. Serheieva
T.A. Serheieva
APA.P. Podavalenko
A.P. Podavalenko
In recent decades, there has been a global trend of increasing incidence of pertussis and changes in its epidemiological characteristics toward re-emergent properties. This trend has become especially pronounced in the post-COVID-19 pandemic period in the European Region (87,558 cases in 2023), including Ukraine (7,545 cases in 2024). One of the reasons for this situation is considered the introduction of the acellular pertussis vaccine (aP) in some countries, due to its shorter duration of post-vaccination immunity and the loss of certain antigens by circulating Bordetella pertussis strains under the pressure of specific post-vaccination antibodies. However, in Ukraine, the whole-cell pertussis vaccine (wP) is currently used for routine immunization. The aim of this work is to summarize scientific information on the biological properties of B. pertussis circulating in different regions and formed under the influence of aP and wP vaccines. The virulence factors of B. pertussis are analyzed, including those with antigenic properties used in aP vaccines. An analysis of existing scientific data on the molecular-genetic and antigenic characteristics of B. pertussis variants using aP and wP vaccines was carried out. It is concluded that long-term vaccination against pertussis, on the one hand, leads to a sharp decrease in the incidence of this infection, and on the other hand, contributes to the further evolution of B. pertussis, promoting changes or loss of certain antigens and further genetic distance from vaccine strains of both aP and wP types. This allowed the pathogen to evade specific immunity at both the individual and population levels and caused an increase in incidence. The aP vaccines accelerate such evolutionary changes to a greater extent. At the same time, the genetic diversity of variants in territories using aP vaccines is greater compared to those using wP (which may even be limited to clonal variants). A trend is observed toward increasing similarity of B. pertussis strains circulating worldwide. This may be due to the same direction of evolutionary changes and intensive population migration processes, which turn the globe into a single epidemic zone. One of the negative trends is the emergence of macrolide-resistant B. pertussis variants, which are widespread in China and still sporadically observed in Europe. All of the above contribute to the loss of vaccine controllability of pertussis and the emergence of a tendency to transition at this stage to re-emergent infections. This requires the widespread implementation of molecular-genetic monitoring in the epidemiological surveillance of pertussis and the improvement of vaccination strategy and tactics based on its results.